Oculus Innovative Sciences Strengthens Intellectual Property Portfolio With Issuance of U.S. Patent for Treatment of Skin Ulcers

Oculus Innovative Sciences Strengthens Intellectual Property Portfolio With
Issuance of U.S. Patent for Treatment of Skin Ulcers With Microcyn(R)
Technology

PETALUMA, Calif., Dec. 27, 2012 (GLOBE NEWSWIRE) -- Oculus Innovative
Sciences, Inc. (Nasdaq: OCLS) a healthcare company that designs, produces and
markets innovative, safe and effective anti-infective products and medical
devices while also developing multiple drug candidates, today announced the
issuance of new U.S. patent for the use of Microcyn® Technology in the
treatment of skin ulcers. In this application, Microcyn Technology can be
delivered to skin ulcers via washing, irrigation and soaking or through
application of a wound dressing saturated in the Microcyn Technology.
According to claims allowed by the patent examiner, the application of the
Microcyn Technology via these methods will:

  *Reduce the microbial load of an infected diabetic foot ulcer;
  *Decrease the recurrence rate of an infected diabetic foot ulcer;
  *Decrease the likelihood of dehiscence of an infected diabetic foot ulcer;
  *Decrease the likelihood of amputation resulting from an infected diabetic
    foot ulcer;
  *Decrease the likelihood of systemic inflammatory response syndrome from an
    infected diabetic foot ulcer;
  *Decrease the likelihood of sepsis resulting from an infected diabetic foot
    ulcer.

Hoji Alimi, founder and CEO of Oculus said: "Skin ulcers, in varying
presentations, are a significant challenge to the well being of millions.In
fact, over six million Americans are afflicted each year with chronic wounds
including arterial, diabetic, pressure and venous ulcers.The Microcyn
Technology, cleared for the management of these ulcers by the FDA, is our
first step into these large markets. This latest patent provides Oculus with
the intellectual property protection necessary for an optimum return on our
commercialization efforts, as well as those of our industry partners." 

The latest-issued patent joins a growing intellectual property estate (either
owned or licensed to Oculus) that now includes 24 issued patents and100+
pending applications directed to chemical compositions,apparatuses, methods
of manufacturing and therapeutic uses.

About Oculus Innovative Sciences

Oculus Innovative Sciences is a healthcare company that designs, produces and
markets innovative, safe and effective anti-infective products and medical
devices while also developing multiple drug candidates for various indications
including treatment of acne and surgical suite use. Oculus is pioneering
innovative solutions in multiple markets for the dermatology, surgical, wound
care, and animal healthcare markets, and has commercialized products in the
United States, Europe, India, China, Mexico and select Middle East countries.
The company's headquarters are in Petaluma, California, with manufacturing
operations in the United States and Latin America. More information can be
found at www.oculusis.com.

Forward-Looking Statements

Except for historical information herein,matters set forth in this press
release are forward-looking within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995, including statements
about the Company's commercial and technology progress and futurefinancial
performance. These forward-looking statements are identified by the use of
words such as "providing," "growing" and"afflicted,"among others.
Forward-looking statements in this press release are subject to certain risks
and uncertainties inherent in the Company's business that could cause actual
results to vary, includingsuchrisks thatregulatory clinical and guideline
developments may change,scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances or
approvals,clinical results may not be replicated in actual patient
settings,protection offered bythe Company'spatents and patent applications
may be challenged, invalidated or circumvented by its competitors,the
available market fortheCompany'sproducts will not be as large as
expected,the Company'sproducts will not be able to penetrate one or more
targeted markets,revenues will not be sufficient to fund further development
and clinical studies, the Company may not meet itsfuture capital needs, and
its ability to obtain additional funding, as well as uncertainties relative to
varying product formulations and a multitude of diverse regulatory and
marketing requirements in different countries and municipalities, and other
risks detailed from time to time in the Company's filings with the Securities
and Exchange Commission including the annual report on Form 10-K for theyear
ended March 31, 2012. Oculus Innovative Sciences disclaims any obligation to
update these forward-looking statements except as required by law.

Oculus and Microcyn Technology are trademarks or registered trademarks of
Oculus Innovative Sciences, Inc. All other trademarks and service marks are
the property of their respective owners.

CONTACT: Media and Investor Contact:
         Oculus Innovative Sciences, Inc.
         Dan McFadden
         Director of Public and Investor Relations
         (425) 753-2105